Anomer Bio arrives at SBC to develop a new class of glycan-targeting therapeutics

The company has checked into the Lab Hotel to accelerate its work on small molecule drugs that block disease-driving glycans.

Stevenage Bioscience Catalyst is delighted to welcome Anomer Bio as the team begins work from the SBC Lab Hotel. The company is exploring a new way of treating disease by focusing not on proteins, but on glycans: the sugars on the surface of cells that play a central role in how the body responds to disease. While most current therapies focus on proteins, Anomer Bio aims to stop cells from producing disease-driving glycans, opening a novel therapeutic avenue that could benefit a wide range of conditions.

The company is co-founded by Sophie James, CEO, and Marcos Burger Ramos, CSO, who are now working from SBC during the next phase of their development.

Co Founder and CEO, Sophie James PhD, says:

“We are super excited to have opened our lab at the SBC Lab Hotel, it’s great to be surrounded by so many early-stage companies doing cool science!”

Sophie brings a background in cancer biology with experience at the Crick Institute, while Marcos brings computational expertise and previous experience at Neobe Therapeutics. Their combined skill sets offer complementary scientific and technical expertise as Anomer Bio progresses its platform.

By joining SBC, Anomer Bio becomes part of a collaborative environment designed to support early stage innovators through shared facilities, peer networks and business support. The team will now benefit from proximity to major partners across industry and investment.

 

If you would like to know more about Anomer Bio or Lab Hotel opportunities, please contact Marco Delise.